Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and… Read more
Taiwan Advance Bio-Pharmaceutical Inc. (4186) - Total Liabilities
Latest total liabilities as of June 2025: NT$439.78 Million TWD
Based on the latest financial reports, Taiwan Advance Bio-Pharmaceutical Inc. (4186) has total liabilities worth NT$439.78 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Taiwan Advance Bio-Pharmaceutical Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Taiwan Advance Bio-Pharmaceutical Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Taiwan Advance Bio-Pharmaceutical Inc. Competitors by Total Liabilities
The table below lists competitors of Taiwan Advance Bio-Pharmaceutical Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fleming Properties AB
ST:FLMNG
|
Sweden | Skr59.39 Million |
|
Tamawood Ltd
AU:TWD
|
Australia | AU$18.85 Million |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
Turkey | TL4.75 Billion |
|
Zelluna ASA
OL:ZLNA
|
Norway | Nkr17.65 Million |
|
Samchuly Bicycle Co. Ltd
KQ:024950
|
Korea | ₩141.49 Billion |
|
TOUBF
PINK:TOUBF
|
USA | $748.64K |
|
Welltend Technology Corp
TW:3021
|
Taiwan | NT$1.68 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Taiwan Advance Bio-Pharmaceutical Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Taiwan Advance Bio-Pharmaceutical Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Taiwan Advance Bio-Pharmaceutical Inc. (2019–2024)
The table below shows the annual total liabilities of Taiwan Advance Bio-Pharmaceutical Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$419.98 Million | -18.39% |
| 2023-12-31 | NT$514.65 Million | +11.37% |
| 2022-12-31 | NT$462.13 Million | -2.15% |
| 2021-12-31 | NT$472.29 Million | +1.67% |
| 2020-12-31 | NT$464.55 Million | +171955.56% |
| 2019-12-31 | NT$270.00K | -- |